Literature DB >> 25899424

Progressive multiple sclerosis and mood disorders.

Lorena Lorefice1, G Fenu, G Trincas, M F Moro, J Frau, G C Coghe, E Cocco, M G Marrosu, M G Carta.   

Abstract

Mood disorders are very common among multiple sclerosis (MS) patients, but their frequency in patients with progressive course (PMS) has not been adequately researched. Our study aimed to determine the frequency of mood disorders among patients with PMS compared with those with relapsing-remitting MS (RMS) and to explore the associations with disability and disease duration. The study included consecutive outpatients affected by MS according the 2010 revised Mc Donald diagnostic criteria. Psychiatric diagnoses were determined according to DSM-IV by psychiatrists using structured interview tools (ANTAS-SCID). Demographic and clinical data of patients were also collected. Disease courses were defined according to the re-examined phenotype descriptions by the Committee and MS Phenotype Group. Intergroup comparisons were performed by Chi-square test, while logistic regression analysis was performed to assess possible factors associated with mood disorders. In total, 240 MS patients (167 women) were enrolled; of these, 18 % (45/240) had PMS. The lifetime DSM-IV major depression diagnosis (MDD) was established in 40 and 23 % of the PMS and RMS patients, respectively. Using logistic regression analysis, the presence of MDD was independent from disease duration and disability and dependent on PMS course (P = 0.02; OR 2.2). Patients with PMS presented with MDD more frequently than those with RMS, independently from disease duration and physical disability. These findings highlight the importance of considering mood disorders, especially MDD, in the management of PMS patients.

Entities:  

Mesh:

Year:  2015        PMID: 25899424     DOI: 10.1007/s10072-015-2220-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  59 in total

1.  Symptomatic therapies in multiple sclerosis. Introduction.

Authors:  Claudio Solaro; Gianluigi Mancardi
Journal:  Neurol Sci       Date:  2008-12       Impact factor: 3.307

2.  Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample.

Authors:  Lydia Chwastiak; Dawn M Ehde; Laura E Gibbons; Mark Sullivan; James D Bowen; George H Kraft
Journal:  Am J Psychiatry       Date:  2002-11       Impact factor: 18.112

Review 3.  Treatment of neuropsychiatric syndromes in multiple sclerosis.

Authors:  Scott B Patten
Journal:  Expert Rev Neurother       Date:  2005-05       Impact factor: 4.618

4.  The effects of anxiety on psychiatric morbidity in patients with multiple sclerosis.

Authors:  A Feinstein; P O'Connor; T Gray; K Feinstein
Journal:  Mult Scler       Date:  1999-10       Impact factor: 6.312

Review 5.  Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes.

Authors:  Heinz Wiendl; Reinhard Hohlfeld
Journal:  Neurology       Date:  2009-03-17       Impact factor: 9.910

Review 6.  Natural history of multiple sclerosis: risk factors and prognostic indicators.

Authors:  Sandra Vukusic; Christian Confavreux
Journal:  Curr Opin Neurol       Date:  2007-06       Impact factor: 5.710

7.  Alcohol and drug abuse among persons with multiple sclerosis.

Authors:  C H Bombardier; K D Blake; D M Ehde; L E Gibbons; D Moore; G H Kraft
Journal:  Mult Scler       Date:  2004-02       Impact factor: 6.312

8.  A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis.

Authors:  Alex Rovira; Josephine Swanton; Mar Tintoré; Elena Huerga; Fredrick Barkhof; Massimo Filippi; Jette L Frederiksen; Annika Langkilde; Katherine Miszkiel; Chris Polman; Marco Rovaris; Jaume Sastre-Garriga; David Miller; Xavier Montalban
Journal:  Arch Neurol       Date:  2009-05

9.  Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study.

Authors:  Claudio Solaro; Roberto Bergamaschi; Cristiana Rezzani; Margit Mueller; Erika Trabucco; Valeria Bargiggia; Francesca Dematteis; Alessandra Mattioda; Vincenzo Cimino; Domenico Restivo; Francesco Patti; Paola Cavalla
Journal:  Clin Neuropharmacol       Date:  2013 Jul-Aug       Impact factor: 1.592

10.  The use of antidepressant drugs and the lifetime prevalence of major depressive disorders in Italy.

Authors:  Mauro Giovanni Carta; Eugenio Aguglia; Alberto Bocchetta; Matteo Balestrieri; Filippo Caraci; Massimo Casacchia; Liliana Dell'osso; Guido Di Sciascio; Filippo Drago; Carlo Faravelli; Maria Efisia Lecca; Maria Francesca Moro; Pier Luigi Morosini; Marcello Nardini; Gabriella Palumbo; Maria Carolina Hardoy
Journal:  Clin Pract Epidemiol Ment Health       Date:  2010-08-27
View more
  3 in total

Review 1.  Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: A systematic review and meta-analysis.

Authors:  Diulle Spat Peres; Patrícia Rodrigues; Fernanda Tibolla Viero; Julia Maria Frare; Sabrina Qader Kudsi; Graziela Moro Meira; Gabriela Trevisan
Journal:  Brain Behav Immun Health       Date:  2022-07-06

2.  Listening to the neurological teams for multiple sclerosis: the SMART project.

Authors:  P Chesi; M G Marini; G L Mancardi; F Patti; L Alivernini; A Bisecco; G Borriello; S Bucello; F Caleri; P Cavalla; E Cocco; C Cordioli; M Di Giuseppe; R Fantozzi; M Gattuso; F Granella; M Liguori; L Locatelli; A Lugaresi; S Marangoni; L Moiola; E Mutta; W Neri; L Pastò; P Perini; M Petruzzo; K Plewnia; A M Repice; M Rezzonico; S Romano; M Rovaris; E Sessa; C Tortorella; R Totaro; P Valentino
Journal:  Neurol Sci       Date:  2020-03-20       Impact factor: 3.307

3.  Vitamin D Supplementation and Mental Health in Multiple Sclerosis Patients: A Systematic Review.

Authors:  Dominika Głąbska; Aleksandra Kołota; Katarzyna Lachowicz; Dominika Skolmowska; Małgorzata Stachoń; Dominika Guzek
Journal:  Nutrients       Date:  2021-11-24       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.